Ultragenyx Pharmaceutical (NASDAQ:RARE) CFO Sells $72,117.16 in Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CFO Howard Horn sold 3,061 shares of the stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $23.56, for a total value of $72,117.16. Following the completion of the sale, the chief financial officer directly owned 88,935 shares of the company’s stock, valued at $2,095,308.60. The trade was a 3.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Howard Horn also recently made the following trade(s):

• On Wednesday, December 10th, Howard Horn sold 3,081 shares of Ultragenyx Pharmaceutical stock. The shares were sold at an average price of $36.38, for a total transaction of $112,086.78.

Ultragenyx Pharmaceutical Stock Performance

Ultragenyx Pharmaceutical stock traded up $0.06 during midday trading on Tuesday, hitting $24.82. 1,189,109 shares of the company’s stock were exchanged, compared to its average volume of 2,816,204. The stock has a market cap of $2.39 billion, a price-to-earnings ratio of -4.18 and a beta of 0.16. Ultragenyx Pharmaceutical Inc. has a 12-month low of $18.41 and a 12-month high of $46.50. The firm’s 50 day simple moving average is $28.87 and its 200 day simple moving average is $29.98.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.58). The business had revenue of $159.93 million for the quarter, compared to analyst estimates of $167.42 million. Ultragenyx Pharmaceutical had a negative return on equity of 414.17% and a negative net margin of 91.95%.Ultragenyx Pharmaceutical’s quarterly revenue was up 14.6% on a year-over-year basis. During the same quarter last year, the company posted ($1.40) EPS. On average, equities research analysts forecast that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Hedge funds and other institutional investors have recently modified their holdings of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Ultragenyx Pharmaceutical by 14.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 232,360 shares of the biopharmaceutical company’s stock worth $8,414,000 after acquiring an additional 29,984 shares during the period. Wealth Enhancement Advisory Services LLC purchased a new stake in Ultragenyx Pharmaceutical during the second quarter worth $353,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in Ultragenyx Pharmaceutical by 18.0% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,652 shares of the biopharmaceutical company’s stock valued at $133,000 after purchasing an additional 557 shares during the last quarter. KLP Kapitalforvaltning AS grew its holdings in Ultragenyx Pharmaceutical by 8.6% in the second quarter. KLP Kapitalforvaltning AS now owns 17,700 shares of the biopharmaceutical company’s stock valued at $644,000 after purchasing an additional 1,400 shares during the last quarter. Finally, Vontobel Holding Ltd. acquired a new position in shares of Ultragenyx Pharmaceutical during the 2nd quarter worth $380,000. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms recently weighed in on RARE. Bank of America lowered their price objective on shares of Ultragenyx Pharmaceutical from $72.00 to $58.00 and set a “buy” rating on the stock in a research report on Friday, January 2nd. TD Cowen cut their price target on shares of Ultragenyx Pharmaceutical from $86.00 to $75.00 and set a “buy” rating for the company in a report on Wednesday, November 5th. Barclays reduced their price objective on shares of Ultragenyx Pharmaceutical from $81.00 to $50.00 and set an “overweight” rating for the company in a research report on Monday, November 24th. HC Wainwright reiterated a “buy” rating and set a $60.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Tuesday. Finally, Truist Financial cut their target price on Ultragenyx Pharmaceutical from $100.00 to $90.00 and set a “buy” rating for the company in a research note on Wednesday, November 5th. Sixteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Ultragenyx Pharmaceutical presently has an average rating of “Moderate Buy” and an average target price of $72.29.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.